

Drug Monograph

Drug/Drug **Albuminex[®] (human albumin) solution for intravenous injection / Blood product derivative**
 Class: **injection / Blood product derivative**
 Prepared for: MO HealthNet
 Prepared by: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Albuminex [®] 5% contains 5 g per dL of human albumin in 250 mL and 500 mL vials. Albuminex [®] 5% contains 25 g per dL of human albumin in 50 mL and 100 mL vials.
Manufacturer:	Distributed by: Bio Products Laboratory USA Inc., Durham, NC 27701.
Indications:	Albuminex [®] is indicated in adults and children for: <ul style="list-style-type: none"> • Hypovolemia • Ascites • Hypoalbuminemia including from burns • Acute Nephrosis • Acute Respiratory Distress Syndrome (ARDS) • Cardiopulmonary Bypass
Costs:	\$70 per 250 ml vial of 5% and \$140 per 100 ml vial of 25% Albuminex [®] . Wholesale Acquisition Cost
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required <input checked="" type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input type="checkbox"/> Preferred <input checked="" type="checkbox"/> Appropriate Indications <input type="checkbox"/> No PA Required

Prepared by: Carrie Gatzke PharmD
 Date: February 21, 2019